ATE110966T1 - Verbessertes behandlungsverfahren für krebs. - Google Patents
Verbessertes behandlungsverfahren für krebs.Info
- Publication number
- ATE110966T1 ATE110966T1 AT92901177T AT92901177T ATE110966T1 AT E110966 T1 ATE110966 T1 AT E110966T1 AT 92901177 T AT92901177 T AT 92901177T AT 92901177 T AT92901177 T AT 92901177T AT E110966 T1 ATE110966 T1 AT E110966T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- chemotherapeutic agent
- cancer cells
- cancer
- antagonist
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 230000002411 adverse Effects 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 229960001340 histamine Drugs 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62786390A | 1990-12-17 | 1990-12-17 | |
| US71197591A | 1991-06-07 | 1991-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE110966T1 true ATE110966T1 (de) | 1994-09-15 |
Family
ID=27090549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92901177T ATE110966T1 (de) | 1990-12-17 | 1991-12-16 | Verbessertes behandlungsverfahren für krebs. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0563127B1 (de) |
| JP (1) | JP2706371B2 (de) |
| AT (1) | ATE110966T1 (de) |
| AU (1) | AU664978B2 (de) |
| CA (1) | CA2098593C (de) |
| DE (1) | DE69103908T2 (de) |
| DK (1) | DK0563127T3 (de) |
| ES (1) | ES2063574T3 (de) |
| WO (1) | WO1992011035A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9303210D0 (en) * | 1993-02-17 | 1993-03-31 | Univ Manitoba | Cancer treatment |
| AU749157B2 (en) * | 1993-02-17 | 2002-06-20 | University Of Manitoba | Cancer treatment |
| US5432168A (en) * | 1993-12-27 | 1995-07-11 | University Of Manitoba | Method of treatment of hormone-unresponsive metastatic prostate cancer |
| US6506876B1 (en) * | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| US5863912A (en) * | 1994-12-07 | 1999-01-26 | Manitoba Cancer Treatment And Research Foundation | Method of treatment of hormone-unresponsive metastiatic prostate cancer |
| EP1280924A2 (de) * | 2000-04-14 | 2003-02-05 | University of South Carolina Research Foundation | Klonierung einer corynebacteriaceae histidine ammonia lyase und therapeutische verwendungen |
| US6630454B2 (en) * | 2001-09-10 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Method and pharmaceutical composition for the treatment of cancer |
| JP2005512996A (ja) * | 2001-11-09 | 2005-05-12 | ユニヴァーシティ オブ マニトーバ | 乳癌の治療 |
| BR0314097A (pt) * | 2002-09-04 | 2005-07-19 | Univ Manitoba | Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano |
| CA3002767C (en) * | 2015-10-27 | 2023-03-14 | Zvi VOGEL | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1229604A (en) * | 1984-02-14 | 1987-11-24 | Lorne J. Brandes | Aminoalkyl ethers of phenols as antiproliferative anticancer agents |
-
1991
- 1991-12-16 DE DE69103908T patent/DE69103908T2/de not_active Expired - Fee Related
- 1991-12-16 AU AU90583/91A patent/AU664978B2/en not_active Ceased
- 1991-12-16 CA CA002098593A patent/CA2098593C/en not_active Expired - Fee Related
- 1991-12-16 JP JP4502021A patent/JP2706371B2/ja not_active Expired - Fee Related
- 1991-12-16 ES ES92901177T patent/ES2063574T3/es not_active Expired - Lifetime
- 1991-12-16 DK DK92901177.3T patent/DK0563127T3/da active
- 1991-12-16 AT AT92901177T patent/ATE110966T1/de not_active IP Right Cessation
- 1991-12-16 WO PCT/CA1991/000449 patent/WO1992011035A1/en active IP Right Grant
- 1991-12-16 EP EP92901177A patent/EP0563127B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992011035A1 (en) | 1992-07-09 |
| CA2098593C (en) | 1999-08-10 |
| DE69103908T2 (de) | 1995-01-05 |
| CA2098593A1 (en) | 1992-06-18 |
| DK0563127T3 (da) | 1994-11-28 |
| EP0563127A1 (de) | 1993-10-06 |
| AU9058391A (en) | 1992-07-22 |
| EP0563127B1 (de) | 1994-09-07 |
| JP2706371B2 (ja) | 1998-01-28 |
| DE69103908D1 (de) | 1994-10-13 |
| JPH06505710A (ja) | 1994-06-30 |
| AU664978B2 (en) | 1995-12-14 |
| ES2063574T3 (es) | 1995-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE110966T1 (de) | Verbessertes behandlungsverfahren für krebs. | |
| BR9604881A (pt) | Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida | |
| KR930003912A (ko) | 울혈성 심장 마비 치료법 | |
| ATE80795T1 (de) | Emulsionen zur verabreichung in wasser schwerloeslicher ionisierbarer basischer hydrophober arzneistoffe. | |
| DK1033981T3 (da) | Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet | |
| BG95935A (bg) | Метод и средство за приемане на дексмедетомидин директно през кожата | |
| WO1998022141A3 (en) | Enhanced effects for hapten conjugated therapeutics | |
| BG42837A3 (bg) | Метод за получаване на имуноглобулинови производни на винка алкалоиди | |
| NO20006604L (no) | Fremgangsmåter og transdermale sammensetninger for lindring av smerte | |
| DE69836222D1 (de) | Modifizierter tumor-nekrosefaktor | |
| Kellner et al. | Toxic hepatitis by clozapine treatment. | |
| TR200101633T2 (tr) | Farmasötik bileşim | |
| AU4258101A (en) | Combination therapies with vascular damaging activity | |
| SE8303003D0 (sv) | Medel for att oka antitumorverkan hos antitumormedel | |
| TR199900951T2 (xx) | G���s kanserinin engellenmesi i�in y�ntemler. | |
| NL194959B (nl) | Preparaat voor het toedienen van ijzer. | |
| EA200400692A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
| ES465215A1 (es) | Procedimiento para la preparacion de compuestos poliomeri- cos. | |
| IL101675A0 (en) | Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors | |
| DE3875611D1 (de) | Pharmazeutische zusammensetzungen. | |
| BR9708525A (pt) | Método de tratamento de insuficência cardíaca com antagonistas de endotelina | |
| PT1058544E (pt) | Inibicao da actividade do tnf | |
| ES2192874T3 (es) | Proteina c para el tratamiento de la enfermedad de la celula con anemia hepatica y talasemia. | |
| DE3368199D1 (en) | Mixture comprising a central analgesic and vitamin b12, or one of its analogs, as active principles | |
| NL186860C (nl) | N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |